BLX 0631
Alternative Names: BLX-0631Latest Information Update: 22 Jun 2024
At a glance
- Originator Biolexis Therapeutics
- Class Antineoplastics
- Mechanism of Action Proto oncogene protein c pim 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple myeloma; Renal cell carcinoma; Systemic lupus erythematosus
Most Recent Events
- 09 Apr 2024 Pharmacodynamics data from a preclinical study in Multiple myeloma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 18 Jan 2024 Biolexis Therapeutics plans to submit IND application for BLX 0631 in Q3 2024 (Biolexis Therapeutics pipeline, January 2024)
- 18 Jan 2024 Biolexis Therapeutics plans a phase I trial for BLX 0631 in Q4 2024 (Biolexis Therapeutics pipeline, January 2024)